GSK Discussing Paxil Pediatric Suicide Link With FDA; Label Change In U.K.

GlaxoSmithKline is discussing with FDA whether Paxil data indicating an increased risk of "emotional lability" in pediatric patients on paroxetine should be communicated to physicians

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet